Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles

Nature Communications

Volumn 7, Issue , 2016, Pages

  Varn, Frederick S ^a   Andrews, Erik H ^a   Mullins, David W ^a   Cheng, Chao ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR MARKER;

BLOOD; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; HOST; IMMUNE RESPONSE; IMMUNE SYSTEM; SURVIVAL; TUMOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC MARKER; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROARRAY ANALYSIS; MONOCYTE; MULTIPLE CANCER; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; PROGNOSIS;

MURINAE;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; PROGNOSIS;

EID: 84953306200     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10248     Document Type: Article

References (49)

1. Junttila, M. R., de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013).
2. Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
3. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
4. Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).
5. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
6. Jojic, V. et al. Identification of transcriptional regulators in the mouse immune system. Nat. Immunol. 14, 633-643 (2013).
7. Shay, T. et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc. Natl Acad. Sci. USA 110, 2946-2951 (2013).
8. Cheng, C., Yan, X., Sun, F., Li, L. M. Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinformatics 8, 452 (2007).
9. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
10. Yuan, Y. et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med. 4, 157ra143 (2012).
11. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M., Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
12. Man, Y. G. et al. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J. Cancer 4, 84-95 (2013).
13. Nakano, O. et al. Proliferative activity of intratumoral CD8(\+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132-5136 (2001).
14. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
15. Sato, E. et al. Intraepithelial CD8\+ tumor-infiltrating lymphocytes and a high CD8\+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538-18543 (2005).
16. Liakou, C. I., Narayanan, S., Ng Tang, D., Logothetis, C. J., Sharma, P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 7, 10 (2007).
17. Ohtani, H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 7, 4 (2007).
18. Mahmoud, S. M. et al. Tumor-infiltrating CD8\+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949-1955 (2011).
19. Negrini, S., Gorgoulis, V. G., Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell. Biol. 11, 220-228 (2010).
20. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
21. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
22. Krummel, M. F., Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
23. Korman, A. J., Peggs, K. S., Allison, J. P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339 (2006).
24. Chan, D. V. et al. Differential CTLA-4 expression in human CD4\+ versus CD8\+ T cells is associated with increased NFAT1 and inhibition of CD4\+ proliferation. Genes Immun. 15, 25-32 (2014).
25. Fulda, S. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Adv. Exp. Med. Biol. 818, 167-180 (2014).
26. Cullen, S. P., Martin, S. J. Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer. Semin. Cell Dev. Biol. 39, 26-34 (2015).
27. Falschlehner, C., Schaefer, U., Walczak, H. Following TRAIL's path in the immune system. Immunology 127, 145-154 (2009).
28. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
29. Chia, S. K. et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res. 18, 4465-4472 (2012).
30. Ur-Rehman, S., Gao, Q., Mitsopoulos, C., Zvelebil, M. ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res. Treat. 139, 907-921 (2013).
31. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
32. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
33. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-5413 (2008).
34. Sboner, A. et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med. Genomics 3, 8 (2010).
35. Lee, E. S. et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin. Cancer Res. 14, 7397-7404 (2008).
36. Abbas, A. R. et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6, 319-331 (2005).
37. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011).
38. Kashii, Y., Giorda, R., Herberman, R. B., Whiteside, T. L., Vujanovic, N. L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 163, 5358-5366 (1999).
39. Kemp, T. J., Elzey, B. D., Griffith, T. S. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2 L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171, 212-218 (2003).
40. Nelson, B. H. CD20\+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185, 4977-4982 (2010).
41. Dunn, G. P., Old, L. J., Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
42. Klebanoff, C. A., Gattinoni, L., Restifo, N. P. CD8\+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214-224 (2006).
43. Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J., Nelson, B. H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434-444 (2014).
44. Djenidi, F. et al. CD8\+CD103\+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475-3486 (2015).
45. Halaas, O., Vik, R., Ashkenazi, A., Espevik, T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand. J. Immunol. 51, 244-250 (2000).
46. Vivier, E. et al. Innate or adaptive immunity The example of natural killer cells. Science 331, 44-49 (2011).
47. Azimi, F. et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 30, 2678-2683 (2012).
48. Suzuki, K. et al. Prognostic immune markers in non-small cell lung cancer. Clin. Cancer Res. 17, 5247-5256 (2011).
49. Gautier, L., Cope, L., Bolstad, B. M., Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004).